Lu, Rufei
Guthridge, Joel M.
Chen, Hua
Bourn, Rebecka L.
Kamp, Stan
Munroe, Melissa E.
Macwana, Susan R.
Bean, Krista
Sridharan, Sudhakar
Merrill, Joan T.
James, Judith A. http://orcid.org/0000-0002-9574-7355
Funding for this research was provided by:
Pfizer
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (U19AI082714, U01AI101934)
U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (P30AR053483, P30AR073750, R01AR072401)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (U54GM104938)
Article History
Received: 12 February 2019
Accepted: 31 May 2019
First Online: 13 June 2019
Change Date: 20 November 2019
Change Type: Correction
Change Details: An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Competing Interests
: Pfizer supported the BOLD clinical trial as an investigator-initiated study to J.T.M. as the principal investigator. Pfizer had no role in the design of the currently reported biomarker work, in the collection, analysis or interpretation of these biomarker data, or in the writing of this manuscript. S.S. is a former employee of Pfizer. J.T.M. and J.A.J. have received research support from Pfizer, and J.T.M. is a consultant for Pfizer. Patents, with inventors J.A.J. and MEM, have been licensed by OMRF to Progentec Biosciences. All other authors declare no competing interests.